{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-047704","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2024-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.433240+00:00","generated_at":"2026-05-29T19:02:01.984656+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"FDA approves BridgeBio's Attruby (acoramidis) for ATTR-CM to reduce CV death and hospitalization","bullets":["Attruby is first and only approved TTR stabilizer with label specifying near-complete stabilization (≥90%).","Phase 3 ATTRibute-CM: 42% reduction in composite ACM and recurrent CVH at Month 30; 50% reduction in cumulative CVH events.","BridgeBio to receive $500M payment under royalty funding agreement upon approval.","List price: $18,759.12 for 28-day supply; free for life for U.S. trial participants.","MAA submitted to EMA; decision expected in 2025; Bayer has exclusive EU commercialization rights."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-047704","json":"https://secwatch.observer/filing/0001140361-24-047704.json","markdown":"https://secwatch.observer/filing/0001140361-24-047704.md","text":"https://secwatch.observer/filing/0001140361-24-047704.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000114036124047704/0001140361-24-047704-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000114036124047704/ef20039071_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T19:02:01.984656+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}